Early recognition and management of irAEs associated with I-O agents may mitigate severe toxicity. Management algorithms have been developed fromextensive experience with I-O agents to assist investigators in assessing and managing the following groups of irAEs: •GI •Renal •Pulmonary •Hepatic •Endocrinopathy •Skin •Neurological Revised Protocol No.: 04 Date: 31-May-2019 87 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS The clinical nature of AEs noted with BMS-98622 6 will determine the role of the algorithms for use in toxicities rel ated to its use in this study. The algorithms reco mmended for the management of irAEs in this protocol are in Appendix 6 . 7.3.4 Dose Delays Due To Toxicity Participants who experience the following mu st have all study treatment(s) withheld: •Potential DLTs, until DLT relatedness is defined. •Select AEs and labor atory abnormalities: −Grade ≥1 pneumonitis −Grade ≥2 abnormality in AST, ALT, or total bilirubin −Grade ≥2 abnormality in creatinine −Grade ≥2 diarrhea or colitis −Grade ≥2 neurological AE −AE, laboratory abnormality, or concurrent illness that, in the judgment of the investigator, warrants delaying study treatment administration. Criteria for participants who are require d to permanently discontinue both st udy tr eatments are listed in Section 8.1 .